KPV

KPV is the three-amino-acid sequence lysine–proline–valine, found at the end of alpha-melanocyte-stimulating hormone. Researchers have studied its ability to reduce inflammatory responses in intestinal cells and mouse colitis. The most informative experiments connect entry through a small-peptide transporter with changes in inflammatory signaling, then examine gut injury in animals. Later work adds a targeted delivery system. Together, these studies explain the interest in KPV for intestinal inflammation; the clinical effectiveness and human safety of a defined KPV medicine remain unresolved.

Overview

The letters K, P and V are the standard one-letter codes for lysine, proline and valine. This short sequence corresponds to residues 11–13 of alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. A fragment can retain some biological activity of its parent while having different transport and receptor behavior. KPV's intestinal research therefore examines the fragment itself and the conditions under which cells take it up. Kannengiesser and colleagues (2008) identify the tested material as alpha-MSH(11–13).

Molecular profile

Peptide sequence: Lys-Pro-Val (KPV) Source
Length: 3 amino-acid residues Source
Parent sequence context: Alpha-MSH residues 11–13 Source
Studied preparations: KPV in cell and mouse studies; a separate nanoparticle/hydrogel formulation Source

Forms and derivatives

KPV nanoparticles in hydrogel

Xiao and colleagues encapsulated KPV in polymer nanoparticles and compared systems with and without a hyaluronic-acid surface. A chitosan/alginate hydrogel carried the particles through the gut. The carrier and surface modification contribute to the identity of the tested intervention.

Uses and research areas

The central research area is intestinal inflammation. Investigators have used human-derived intestinal and immune cell lines, chemically induced mouse colitis, and a mouse model driven by transferred immune cells. These systems reveal different parts of the problem: a cell assay can identify transport and signaling, while an animal experiment can measure weight recovery, inflammatory-cell accumulation and the appearance of intestinal tissue. The reviewed studies supply no controlled patient outcome for Crohn's disease, ulcerative colitis or nonspecific digestive symptoms. Dalmasso and colleagues (2008), Kannengiesser and colleagues (2008).

Delivery has become a separate research focus because a peptide must reach the relevant tissue in an active form. Xiao and colleagues (2017) studied KPV inside polymer nanoparticles with a hyaluronic-acid surface and a protective hydrogel. That preparation introduces a carrier, tissue targeting and release behavior alongside the peptide's biology.

Mechanism of action

How transport connects to inflammatory signaling

PepT1 is a membrane transporter that moves small peptides into cells. Dalmasso and colleagues compared intestinal cell lines with different PepT1 expression, used labeled KPV to examine uptake, and tested competition with other transported peptides. Their findings link PepT1-dependent entry to reduced inflammatory signaling. In stimulated intestinal and Jurkat immune cells, KPV lowered activation of NF-kappaB, a regulator of inflammatory gene expression, and reduced inflammatory cytokine output. The transport experiments help explain why the response depended on the cellular system. Dalmasso and colleagues (2008).

KPV's relationship to alpha-MSH also raises the question of whether it acts through the same receptor. Kannengiesser's experiments included mice with a nonfunctional melanocortin-1 receptor, or MC1R. KPV still reduced inflammatory changes in those animals, suggesting that part of its response can occur without normal MC1R signaling. The experiments did not identify every step between KPV entering a cell and the change in inflammation. Kannengiesser and colleagues (2008).

Pharmacokinetics

Pharmacokinetics describes where a compound goes and how its concentration changes over time. The KPV papers reviewed here address cellular uptake and intestinal delivery, but supply no verified human concentration–time profile or elimination half-life for a defined preparation and route. Transport into a cultured cell, fluorescence from a labeled carrier and persistence of an inflammatory response answer different questions about exposure.

For the nanoparticle formulation, the carrier's movement through the gut is part of the experiment. A label attached to nanoparticles can show where that carrier accumulates; it does not by itself measure the amount of intact KPV in human blood. This distinction matters when comparing the targeted preparation with plain peptide or a commercial mixture. Xiao and colleagues (2017).

Research findings

Chemical injury and immune-driven colitis

Dalmasso's animal work used dextran sodium sulfate, or DSS, and trinitrobenzene sulfonic acid, or TNBS, to induce intestinal inflammation. KPV was supplied in drinking water. The investigators reported improved inflammatory measurements, including tissue appearance and cytokine expression. These experiments connect the earlier cell findings with a response in an intact digestive system. Dalmasso and colleagues (2008).

Kannengiesser's study combined DSS colitis with CD45RB-high transfer colitis, in which transfer of a selected T-cell population produces intestinal inflammation. KPV-treated mice recovered weight and had less inflammatory change in the colon. The immune-transfer model broadens the biological context beyond direct chemical injury. The publication also reports survival of the treated MC1R-deficient animals during DSS colitis; the accessed abstract supplies no group denominator for that finding, so it cannot support a numerical survival estimate here. Kannengiesser and colleagues (2008).

A formulation that changes delivery

Xiao's team enclosed KPV in polymer nanoparticles carried within a chitosan/alginate hydrogel. They compared particles with and without a hyaluronic-acid coating. The coated particles entered colonic epithelial cells and macrophages more readily, and the preparation reduced intestinal injury and inflammatory measurements in mice with chemically induced colitis. The comparison tests the contribution of that surface coating to this delivery system; it does not isolate the effect of plain KPV. Xiao and colleagues (2017).

Safety and tolerability

Human safety cannot be estimated from the reviewed cell and mouse studies. FDA's current bulk-substance safety discussion states that the agency has identified no human exposure data for drug products containing KPV by any route, leaving important information about potential harm unavailable. KPV has no FDA-approved medicinal product identified in this review. FDA safety-risk summary.

The absence of a clear adverse response in a laboratory cell assay covers the assay's cells, measurements and observation period. Human allergic or immune reactions, effects of repeated exposure, interactions and the safety of a particular commercial preparation require their own evidence. Formulation and material quality become especially consequential when the exact preparation differs from the one studied.

What the research means

KPV has a coherent preclinical rationale: small-peptide transport is connected with reduced inflammatory signaling, and separate mouse models show changes in intestinal disease measurements. The targeted-delivery paper adds evidence that the formulation can influence where the intervention reaches and how it performs. This progression makes KPV useful for studying intestinal inflammation and drug delivery.

The next clinical question is whether a characterized preparation can improve outcomes that matter to patients, with reliable exposure and safety measurements. Mouse weight recovery, cell-layer behavior and inflammatory gene expression help choose that experiment, but they cannot determine the benefit a person would experience. From models to people explains how those measurements fit into clinical translation.

FAQs

Has KPV been tested as a treatment in people?

The primary outcome papers reviewed here used cell lines and mice. FDA's KPV safety discussion states that the agency has identified no human exposure data for KPV drug products by any route. The reviewed evidence supplies no controlled patient benefit or dependable human adverse-event rate.

How can such a short peptide affect intestinal cells?

Cells have transport systems for small peptides. KPV's transport experiments linked entry through PepT1 with a change in the inflammatory response. The effect depends on the cell's transport and signaling environment; sequence length alone does not determine biological activity. The mechanism section explains that connection.

Does the targeted nanoparticle study apply to plain KPV?

The experiment compared defined carrier systems that differ in surface modification. Its result includes how those particles reach and enter target cells. A plain-peptide preparation would need its own delivery and outcome measurements to establish the same behavior.

What is KPV's human half-life?

A verified human elimination half-life was not available in the acquired primary sources. Cellular uptake and intestinal carrier imaging cannot supply that value. The pharmacokinetics explanation describes the measurements required to interpret a concentration–time curve.

Is KPV in KLOW?

The commercial composition source reviewed for KLOW lists KPV alongside GHK-Cu, BPC-157 and TB-500. The complete mixture requires its own identity, interaction and outcome evidence. KPV's gut-delivery studies remain attached to their actual preparations.

Larazotide approaches intestinal disease through tight-junction regulation and has a clinical celiac-disease trial program. Reading the two profiles together shows how transport and inflammatory signaling differ from barrier regulation, and how patient trials can produce a more complicated result than cell experiments. KLOW is a commercial mixture whose stated composition includes KPV; its evidence depends on identifying and testing the complete preparation.

References

The original papers below describe the tested models and preparations. The FDA source addresses human exposure and safety gaps.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008; 134(1):166–178. DOI: 10.1053/j.gastro.2007.10.026.
Transport and inflammatory-signaling experiments in human-derived cell lines were paired with DSS and TNBS mouse colitis studies.
Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases. 2008;14(3):324–331. DOI: 10.1002/ibd.20334.
Separates DSS injury from immune-cell-transfer colitis and includes animals with a nonfunctional melanocortin-1 receptor.
Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy. 2017;25(7):1628–1640. DOI: 10.1016/j.ymthe.2016.11.020.
Compares defined KPV nanoparticle/hydrogel systems and connects the hyaluronic-acid surface with cellular uptake and intestinal outcomes.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current agency webpage, checked 2026-10-13.
FDA's KPV entry describes the absence of identified human exposure data and the resulting safety-information gap.

Glossary

Tripeptide: A peptide made of three amino-acid residues.
PepT1: A cell-membrane transporter that carries small peptides into cells.
NF-kappaB: A regulator that helps cells turn on genes involved in inflammation.
Cytokine: A signaling protein through which cells influence inflammation and other responses.
Colitis: Inflammation of the colon; experimental models can produce it through different kinds of injury or immune activity.
Hydrogel: A water-rich polymer network used here to carry nanoparticles through the digestive tract.